Nucleic Acids Research Advance Access originally published online on December 23, 2007
Nucleic Acids Research 2008 36(4):1153-1162; doi:10.1093/nar/gkm1113
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nucleic Acids Research, 2008, Vol. 36, No. 4 1153-1162
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
RNA |
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver
1Santaris Pharma, Bøge Allé 3, DK-2970 Hørsholm and 2Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark
*To whom correspondence should be addressed. Tel: +45 45 17 98 38; Fax: +45 45 17 98 98; Email: sk{at}santaris.com
Received June 28, 2007. Revised November 27, 2007. Accepted November 28, 2007.
MicroRNA-122 (miR-122) is an abundant liver-specific miRNA, implicated in fatty acid and cholesterol metabolism as well as hepatitis C viral replication. Here, we report that a systemically administered 16-nt, unconjugated LNA (locked nucleic acid)-antimiR oligonucleotide complementary to the 5' end of miR-122 leads to specific, dose-dependent silencing of miR-122 and shows no hepatotoxicity in mice. Antagonism of miR-122 is due to formation of stable heteroduplexes between the LNA-antimiR and miR-122 as detected by northern analysis. Fluorescence in situ hybridization demonstrated uptake of the LNA-antimiR in mouse liver cells, which was accompanied by markedly reduced hybridization signals for mature miR-122 in treated mice. Functional antagonism of miR-122 was inferred from a low cholesterol phenotype and de-repression within 24 h of 199 liver mRNAs showing significant enrichment for miR-122 seed matches in their 3' UTRs. Expression profiling extended to 3 weeks after the last LNA-antimiR dose revealed that most of the changes in liver gene expression were normalized to saline control levels coinciding with normalized miR-122 and plasma cholesterol levels. Combined, these data suggest that miRNA antagonists comprised of LNA are valuable tools for identifying miRNA targets in vivo and for studying the biological role of miRNAs and miRNA-associated gene-regulatory networks in a physiological context.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Edson, A. K. Nagaraja, and M. M. Matzuk The Mammalian Ovary from Genesis to Revelation Endocr. Rev., October 1, 2009; 30(6): 624 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Guo Epigenetics of endometriosis Mol. Hum. Reprod., October 1, 2009; 15(10): 587 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. C. Ohlsson Teague, C. G. Print, and M. L. Hull The role of microRNAs in endometriosis and associated reproductive conditions Hum. Reprod. Update, September 22, 2009; (2009) dmp034v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Worm, J. Stenvang, A. Petri, K. S. Frederiksen, S. Obad, J. Elmen, M. Hedtjarn, E. M. Straarup, J. B. Hansen, and S. Kauppinen Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF Nucleic Acids Res., September 1, 2009; 37(17): 5784 - 5792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kato, L. Arce, and R. Natarajan MicroRNAs and Their Role in Progressive Kidney Diseases Clin. J. Am. Soc. Nephrol., July 1, 2009; 4(7): 1255 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gatfield, G. Le Martelot, C. E. Vejnar, D. Gerlach, O. Schaad, F. Fleury-Olela, A.-L. Ruskeepaa, M. Oresic, C. C. Esau, E. M. Zdobnov, et al. Integration of microRNA miR-122 in hepatic circadian gene expression Genes & Dev., June 1, 2009; 23(11): 1313 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Katoh, Y. Sakaguchi, K. Miyauchi, T. Suzuki, S.-i. Kashiwabara, T. Baba, and T. Suzuki Selective stabilization of mammalian microRNAs by 3' adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2 Genes & Dev., February 15, 2009; 23(4): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, L. F. Sempere, F. Galimberti, S. J. Freemantle, C. Black, K. H. Dragnev, Y. Ma, S. Fiering, V. Memoli, H. Li, et al. Uncovering Growth-Suppressive MicroRNAs in Lung Cancer Clin. Cancer Res., February 15, 2009; 15(4): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Petri, M. Lindow, and S. Kauppinen MicroRNA Silencing in Primates: Towards Development of Novel Therapeutics Cancer Res., January 15, 2009; 69(2): 393 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Davis, S. Propp, S. M. Freier, L. E. Jones, M. J. Serra, G. Kinberger, B. Bhat, E. E. Swayze, C. F. Bennett, and C. Esau Potent inhibition of microRNA in vivo without degradation Nucleic Acids Res., January 1, 2009; 37(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Xiao, Z. Zuo, G. Cai, S. Kang, X. Gao, and T. Li miRecords: an integrated resource for microRNA-target interactions Nucleic Acids Res., January 1, 2009; 37(suppl_1): D105 - D110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. E. Nicolas, H. Pais, F. Schwach, M. Lindow, S. Kauppinen, V. Moulton, and T. Dalmay Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140 RNA, December 1, 2008; 14(12): 2513 - 2520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. van Rooij, W. S. Marshall, and E. N. Olson Toward MicroRNA-Based Therapeutics for Heart Disease: The Sense in Antisense Circ. Res., October 24, 2008; 103(9): 919 - 928. [Abstract] [Full Text] [PDF]
|
|